The Porcine Coronary Model of In-Stent Restenosis: Current Status in the Era of Drug-Eluting Stents

Catheterization and Cardiovascular Interventions

Volumn 60, Issue 4, 2003, Pages 515-523

  Lowe, Harry C ^a,d   Schwartz, Robert S ^b   Mac Neill, Briain D ^a   Jang, Ik Kyung ^a   Hayase, Motoya ^a   Rogers, Campbell ^c   Oesterle, Stephen N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ANZAC Research Institute   (Australia)

Author keywords

Animal model; Restenosis; Stent

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ATHEROSCLEROSIS; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; CORONARY STENT; DRUG DELIVERY SYSTEM; ELUTION; HEART CATHETERIZATION; IN STENT RESTENOSIS; MOLECULAR BIOLOGY; NONHUMAN; RESTENOSIS; REVIEW;

ANIMALS; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; STENTS; SWINE;

EID: 0345275858     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10705     Document Type: Review

References (51)

1. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002;87:305-307.
2. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents - part 1. Circulation 2003;107:2274-2279.
3. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
4. Park SJ, Shim W, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
5. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
6. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
7. Teirstein PS. Living the dream of no restenosis. Circulation 2001;104:1996-1998.
8. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-2295.
9. Schwartz RS, Murphy J, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990;82:2190-2200.
10. Virmani R, Kolodgie F, Farb A, Lafont S. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-138.
11. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: on behalf of the subcommittee on animal, cellular and molecular models of thrombosis and haemostasis of the scientific and standardization committee of the international society of thrombosis and haemostasis. Thrombo Haemost 1999;81:835-843.
12. Hughes HC. Swine in cardiovascular research. Lab Ann Sci 1986;36:348-350.
13. Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis parameters in animals. Arzneimittelforschung 1994;44:793-797.
14. Denis CV, Wagner DD. Insights from von Willebrand disease animal models. Cell Mol Life Sci 1999;56:977-990.
15. Verdouw PD, van den Doel MA, de Zeeuw S, Duncker DJ. Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res 1998;39:121-135.
16. Mason R, Read M. Some species differences in fibrinolytics and blood coagulation. J Biomed Mat Res 1971;5:121-128.
17. Gross DR. Animal models in cardiovascular research. Boston: Kluwer Academic; 1994.
18. Kantor B, Ashai K, Holmes DR Jr, Schwartz RS. The experimental animal models for assessing treatment of restenosis. Cardiovasc Radiat Med 1999;1:48-54.
19. Pomerantsev EV, Kim C, Kernoff RS, Oesterle SN, Yeung A, Fitzgerald PJ, Virmani R, Yock PG, Stertzer SH. Coronary AVE micro stents: serial quantitative angiography and histology in a canine model. Cathet Cardiovasc Diagn 1997;41:213-224.
20. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002;90:488-494.
21. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thrombo Vasc Biol 1996;16:1312-1318.
22. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, Palasis M, Yang D, Nott SH, Rogers C. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-2332.
23. Garasic JM, Edelman ER, Squire JC, Seifert P, Williams MS, Rogers C. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 2000;101:812-818.
24. Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thrombo Vasc Biol 2002;22:1769-1776.
25. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
26. Gunn J, Arnold N, Chan KH, Shephard L, Cumberland DC, Crossman DC. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart 2002;88:410-415.
27. Frimerman A, Welch PJ, Jin X, Eigler N, Yei S, Forrester J, Honda H, Makkar R, Barber J, Litvack F. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999;99:697-703.
28. Edelman ER, Seifart P, Groothuis A, Morss A, Bornstein D, Rogers C. Gold-coated NIR stents in porcine coronary arteries. Circulation 2001;103:429-434.
29. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-1873.
30. Lowe HC, Kumar RK, Chesterman CN, Fahmy RG, Khachigian LM. Coronary stent thrombosis: insights from the porcine coronary stent model. Thrombo Haemost 2001;86:937-938.
31. Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res 2001;89:670-677.
32. Malik N, Gunn J, Holt CM, Shepherd L, Francis SE, Newman CM, Crossman DC, Cumberland DC. Intravascular stents: a new technique for tissue processing for histology, immunohistochemistry, and transmission electron microscopy. Heart 1998;80:509-516.
33. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol 1994;24:1398-1405.
34. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
35. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998;81:4E-6E.
36. Lowe HC, Chesterman CN, Khachigian LM. Does thrombus contribute to in-stent restenosis in the porcine coronary stent model? Thrombo Haemost 2001;85:1117-1118.
37. De Scheerder I, Wang K, Wilczek K, Meuleman D, Van Amsterdam R, Vogel G, Piessens J, Van de Werf F. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997;95:1549-1553.
38. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230.
39. Schwartz RS. Animal models of coronary restenosis. In: Topol EJ, editor. Textbook of interventional cardiology. Philadelphia: W.B. Saunders. p 365-381
40. Taylor AJ, Gorman PD, Kenwood B, Hudak C, Tashko G, Virmani R. A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model. Catheter Cardiovasc Interv 2001;53:420-425.
41. Klugherz BD, Jones PL, Cui X, Chen W, Meneveau NF, DeFelice S, Connolly J, Wilensky RL, Levy RJ. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat Biotechnol 2000;18:1181-1184.
42. Klugherz BD, Song C, DeFelice S, Cui X, Lu Z, Connolly J, Hinson JT, Wilensky RL, Levy RJ. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002;13:443-454.
43. Bult H. Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 2000;21:274-279.
44. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193.
45. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
46. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-383.
47. St Clair RW. Atherosclerosis regression in animal models: current concepts of cellular and biochemical mechanisms. Prog Cardiovasc Dis 1983;26:109-132.
48. Stanton HC, Mersmann HJ. Swine in cardiovascular research. Boca Raton, LA: CRC Press; 1986.
49. Rapacz J, Hazler-Rapacz J, Taylor KM, Checovich WJ, Attie AD. Lipoprotein mutations in pigs are associated with elevated plasma cholesterol and atherosclerosis. Science 1986;234:1573-1577.
50. Keelan PC, Baye-Genis A, Kantor B, Singh RJ, Carlson PJ, Lewis DA, Schwartz RS. A novel porcine model for in vivo detection of vulnerable plaque: deposition and localization of lipid-rich lesions in the coronary artery wall. Circulation 2001;104:II67
51. Bouma BE, Tearney G, Yabushita H, Shishkov M, Kauffman CR, DeJoseph Gauthier D, MacNeill BD, Houser SL, Aretz HT, Halpern EF, Jang IK. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003;89:317-320.